Bonita David P 4

What Happened

• Bonita David (Director) is listed on a Form 4 reporting acquisitions on April 14, 2026 of a total of 721,292 derivative securities (reported as purchases). These are pre-funded warrants issued in a private placement: 336,603 and 384,689 pre-funded warrants in two line items. The purchase price per pre-funded warrant was $5.199, implying total consideration of roughly $3.75 million. Pre-funded warrants are derivatives that can be exercised into common shares.

Key Details

• Transaction date: April 14, 2026 (reporting period 2026-04-14).
• Instruments: Pre-funded warrants (derivative acquisitions), two entries of 336,603 and 384,689 for a total of 721,292.
• Price: $5.199 per pre-funded warrant (per footnote); total ≈ $3.75M.
• Exercise terms: Warrants exercisable any time after issuance, subject to a 19.99% beneficial ownership blocker; they expire once exercised in full.
• Record holders: The warrants are held of record by OrbiMed Private Investments VI, LP and OrbiMed Genesis Master Fund, L.P.; related OrbiMed entities may have voting/investment power per footnotes.
• Beneficial-ownership note: Footnotes state the reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest.
• Shares owned after transaction / filing timeliness: Not specified in the provided data.

Context

• Pre-funded warrants are a way for investors to buy near-term rights to common shares (they become common stock upon exercise). The 19.99% blocker prevents immediate exercise that would push ownership above that threshold without further approvals.
• This report documents a private placement to institutional investors (OrbiMed funds); footnotes indicate these are record-held by funds and include standard disclaimers about beneficial ownership — meaning the filing reflects the private-placement structure and related reporting, not necessarily a personal cash purchase by the director in the usual open-market sense.